Addison's disease is a rare condition which in most cases is caused by autoimmune destruction
of the adrenals, leading to deficiency of cortisol, aldosterone and adrenal androgens.
Unrecognized the disease is life threatening, but with proper treatment patients can live
near normal lives.
The conventional glucocorticoid replacement therapy renders the cortisol levels
unphysiological, which may cause symptoms and long-term complications. Glucocorticoid
replacement therapy is technically feasible by continuous subcutaneous hydrocortisone
infusion (CSHI), and can mimic the normal diurnal cortisol rhythm. This study aims to further
evaluate CSHI treatment in terms of metabolic effects, effects on health-related
quality-of-life and sleep in an 8 months randomised open label clinical trial with crossover
design.